However, there is an increased risk of cardiovascular adverse events, including pulmonary embolisms, arterial hypertension and left ventricular ejection fracture with dual BRAF and MEK inhibitor therapy compared to BRAF monotherapy (84). The gene discussed is BRAF; the disease is Hypertension.